Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Bone Remodeling and Repair01:31

Bone Remodeling and Repair

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Role of Vitamins in Maintaining Bone Health01:25

Role of Vitamins in Maintaining Bone Health

The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Essential Minerals for Bone Health01:31

Essential Minerals for Bone Health

The minerals contained in all of the food we consume are essential for our organ systems. However, certain essential minerals, such as calcium, phosphorus, magnesium, manganese, and fluoride, largely affect bone health.
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacodynamics of sustained levels of PTH following palopegteriparatide treatment in adults with hypoparathyroidism.

Journal of the Endocrine Society·2026
Same author

Increased Prevalence of Coronary Artery Calcification in Patients with Post-Surgical Hypoparathyroidism.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same author

Sustained Improvement in Renal Function with Palopegteriparatide in Adults with Chronic Hypoparathyroidism: 2-Year Results from the Phase 3 PaTHway-Trial.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same author

Intratrabecular bone remodeling - a previously overlooked mode of remodeling hyperactivated by parathyroid hormone.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same author

Understanding hypoparathyroidism as a disease of broad functional deficiency.

Trends in endocrinology and metabolism: TEM·2026
Same author

Palopegteriparatide for Adults with Chronic Hypoparathyroidism: Skeletal Dynamics Through 3 yr of the Phase 2 paTH Forward Trial.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026

Related Experiment Video

Updated: Jun 4, 2026

Studies on the Anti-Inflammatory Effect of Xiaoyao Pills in The Treatment of Postmenopausal Osteoporosis in Mice
07:20

Studies on the Anti-Inflammatory Effect of Xiaoyao Pills in The Treatment of Postmenopausal Osteoporosis in Mice

Published on: August 23, 2024

[Denosumab--a new efficient osteoporosis therapy].

Lars Rejnmark1, Peter Vestergaard, Leif Mosekilde

  • 1Medicinsk-endokrinologisk Afdeling, Århus Universitetshospital, Århus Sygehus, THG, Aarhus C, Denmark. rejnmark@post6.tele.dk

Ugeskrift for Laeger
|February 1, 2011
PubMed
Summary

Denosumab, a monoclonal antibody treatment for osteoporosis, significantly boosts bone density and reduces fracture risk in postmenopausal women and men with hypogonadism. Administered via injection, it offers a safe and effective option with few side effects.

More Related Videos

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
08:53

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

Related Experiment Videos

Last Updated: Jun 4, 2026

Studies on the Anti-Inflammatory Effect of Xiaoyao Pills in The Treatment of Postmenopausal Osteoporosis in Mice
07:20

Studies on the Anti-Inflammatory Effect of Xiaoyao Pills in The Treatment of Postmenopausal Osteoporosis in Mice

Published on: August 23, 2024

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
08:53

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

Area of Science:

  • Biologics and immunology
  • Bone metabolism and osteoporosis
  • Pharmacology and therapeutics

Context:

  • Osteoporosis is a prevalent skeletal disorder characterized by low bone mass and microarchitectural deterioration, leading to increased fracture risk.
  • Current osteoporosis treatments aim to reduce bone resorption and enhance bone formation.
  • Denosumab represents a novel therapeutic approach targeting the RANKL pathway.

Purpose:

  • To evaluate the efficacy and safety of denosumab in treating osteoporosis.
  • To assess the impact of denosumab on bone mineral density (BMD) and fracture incidence.
  • To compare denosumab's effects against placebo in relevant patient populations.

Summary:

  • Denosumab, a monoclonal antibody, is administered subcutaneously (60 mg twice yearly) as an antiresorptive therapy for osteoporosis.
  • In postmenopausal women, three-year treatment increased BMD by 6-9% and reduced vertebral and hip fracture risk by 68% and 40%, respectively.
  • In men with cancer-related hypogonadism, denosumab decreased vertebral fracture risk by 62%.

Impact:

  • Denosumab demonstrates significant efficacy in improving bone mineral density and reducing fracture risk in diverse osteoporosis patient groups.
  • The treatment is associated with a favorable safety profile, with few reported side effects, primarily a potential increased risk of infections.
  • This biological therapy offers a valuable new option for managing osteoporosis and preventing debilitating fractures.